AGE-SPECIFIC, PROSTATE-SPECIFIC ANTIGEN (PSA) RANGES IN AFRICAN AMERICANS

非裔美国人的年龄特异性、前列腺特异性抗原 (PSA) 范围

• 批准号: 6237681
• 负责人: JOSEPH E OESTERLING
• 金额: $ 19.65万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 1998-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6237681
• 关键词: African American; age difference; body weight; cancer risk; caucasian American; diagnosis design /evaluation; diet; dietary lipid; family genetics; human age group; human middle age (35-64); human old age (65+); human population study; human subject; interview; male; neoplasm /cancer diagnosis; obesity; prostate preneoplastic state; prostate specific antigen; questionnaires; racial /ethnic difference; urinary tract disorder

Prostate cancer is currently the most common cancer diagnosed and ranks second after lung cancer as the underlying cause of death among men in the United States. Current concerns about the control of prostate cancer have been directed toward early detection and intervention. Since 1987, the measurement of serum prostate-specific antigen (PSA) has led to dramatic increases in the detection of prostate cancer, presumably at earlier stages and at younger ages. Recent work has suggested that the measurement of different molecular forms of serum PSA in the peripheral circulation, or correcting PSA values for patient age, may enhance its diagnostic characteristics, however, most of our knowledge of these markers is based on Caucasian populations. Whereas the incidence and mortality rates of prostate cancer are significantly higher among African Americans than North American whites, it is currently unknown how serum PSA should be used in African-American men. It is our hypothesis that age-specific reference ranges and molecular forms of PSA will be similar in North American African Americans and whites (null hypothesis). To test this a random sample of approximately 500 healthy African-American men, 40-79 years of age inclusive, residing in Genesee County, Michigan, will be asked to participate in a cross-sectional, community-based study that will determine appropriate reference ranges for serum prostate-specific antigen (PSA). The age-specific distribution of free and complexed PSA, and PSA density (PSA/prostatic volume) will be assessed. Each subject will be evaluated for obstructive urinary tract symptoms, and examined by digital rectal (DRE) and transrectal ultrasonography (TRUS). Prior to the scheduled clinical examination, an interview will be conducted in the home of each participant using a standardized pre-tested questionnaire that will gather information on possible risk factors for prostate cancer and benign prostatic hyperplasia (BPH). At the time of the clinical examination, additional blood samples will be obtained and prepared for frozen storage in anticipation of future epidemiologic investigations. These studies will establish how serum PSA, new molecular forms of PSA, and PSA density should be interpreted in African Americans.

前列腺癌是目前诊断和排名最常见的癌症